Research analysts at StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a research report issued on Thursday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Price Performance
Evoke Pharma stock opened at $0.48 on Thursday. The stock has a market capitalization of $4.05 million, a P/E ratio of -0.21 and a beta of 0.22. Evoke Pharma has a 12-month low of $0.42 and a 12-month high of $2.42. The firm’s 50-day moving average is $0.62 and its two-hundred day moving average is $0.93.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last released its earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.59) EPS for the quarter. Evoke Pharma had a negative net margin of 150.43% and a negative return on equity of 517.99%. The business had revenue of $1.68 million during the quarter.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Recommended Stories
- Five stocks we like better than Evoke Pharma
- Health Care Stocks Explained: Why You Might Want to Invest
- Comprehensive Analysis of PayPal Stock
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Intuitive Surgical Stock Can Trend Much Higher This YearÂ
- 3 Fintech Stocks With Good 2021 Prospects
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
